{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:47:47Z","timestamp":1777466867511,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["731.015.413"],"award-info":[{"award-number":["731.015.413"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.nucmedbio.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T02:29:36Z","timestamp":1635474576000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia"],"prefix":"10.1016","volume":"102-103","author":[{"given":"Anna","family":"Pees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"Beaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther J.M.","family":"Kooijman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariska","family":"Verlaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Schuit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.W.D.","family":"Vosjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton F.","family":"Engelsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle J.","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0005","first-page":"145","volume":"374","author":"Fraser","year":"2009"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0010","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.clinthera.2005.11.015","article-title":"Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism","volume":"27","author":"Dong","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00061.2002","article-title":"Mechanisms of secondary hyperparathyroidism","volume":"283","author":"Silver","year":"2002","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0020","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0025","first-page":"168","volume":"391","author":"Bilezikian","year":"2018"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0030","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.surg.2009.09.009","article-title":"Neurocognitive dysfunction: a predictor of parathyroid hyperplasia","volume":"146","author":"Repplinger","year":"2009","journal-title":"Surgery"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0035","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1148\/radiol.2016160768","article-title":"F fluorocholine PET\/MR imaging in patients with and inconclusive conventional imaging: a prospective pilot study","volume":"284","author":"Kluijfhout","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tetlet.2007.11.030","article-title":"Practical synthesis of the calcimimetic agent, cinacalcet","volume":"49","author":"Thiel","year":"2008","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/157015907781695982","article-title":"Allosteric modulation of the calcium-sensing receptor","volume":"5","author":"Jensen","year":"2007","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0050","first-page":"4789","article-title":"Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca2+ set-point in patients with primary hyperparathyroidism","volume":"85","author":"Cetani","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0055","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1523-1755.2000.00370.x","article-title":"Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism","volume":"58","author":"Yano","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0060","author":"The Human Protein Atlas"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0065","first-page":"1177","article-title":"Synthesis of [18F]Fluoroform with high molar activity","volume":"2020","author":"Pees","year":"2020"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0070","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jo202566h","article-title":"Copper-catalyzed oxidative trifluoromethylation of terminal alkynes and aryl boronic acids using (trifluoromethyl)trimethylsilane","volume":"77","author":"Jiang","year":"2012","journal-title":"J Org Chem"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0075","series-title":"Process for preparing cinacalcet and pharmaceutically acceptable salts thereof. WO 2010\/004588 A2","author":"Chidambaram","year":"2010"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0080","first-page":"12551","article-title":"Copper-promoted trifluoromethylation of primary and secondary alkylboronic acids","volume":"51","author":"Xu","year":"2012"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0085","series-title":"Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride. WO 2010\/015935 A2","author":"Sebastian","year":"2010"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0090","doi-asserted-by":"crossref","first-page":"11046","DOI":"10.1002\/anie.201406221","article-title":"A universal procedure for the [18F]trifluoromethylation of aryl iodides and aryl boronic acids with highly improved specific activity","volume":"53","author":"van der Born","year":"2014","journal-title":"Angew Chemie Int Ed"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":"Metabolism and disposition of calcimimetic agent cinacalcet HCL in humans and animal models","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0100","author":"Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0105","volume":"Volume 57","author":"Witty","year":"2018"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1523-1755.2000.00837.x","article-title":"Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism","volume":"57","author":"Wada","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0115","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","article-title":"Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats","volume":"11","author":"Chin","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0120","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","article-title":"Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies","volume":"22","author":"Drueke","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0125","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00198-015-3203-1","article-title":"The calcium-sensing receptor in bone metabolism: from bench to bedside and back","volume":"26","author":"Cianferotti","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nucmedbio.2021.10.003_bb0130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrendo.2015.30","article-title":"The calcium-sensing receptor in bone-mechanistic and therapeutic insights","volume":"11","author":"Goltzman","year":"2015","journal-title":"Nat Rev Endocrinol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121005096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121005096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:29Z","timestamp":1760848229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805121005096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":26,"alternative-id":["S0969805121005096"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.10.003","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}